Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Total Current Liabilities (2020 - 2025)

Bioventus' Total Current Liabilities history spans 6 years, with the latest figure at $160.4 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 23.77% year-over-year to $160.4 million; the TTM value through Dec 2025 reached $160.4 million, down 23.77%, while the annual FY2025 figure was $160.4 million, 23.77% down from the prior year.
  • Total Current Liabilities reached $160.4 million in Q4 2025 per BVS's latest filing, down from $161.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $304.0 million in Q4 2022 to a low of $149.0 million in Q2 2021.
  • Average Total Current Liabilities over 5 years is $191.6 million, with a median of $177.3 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: surged 79.44% in 2022, then plummeted 44.22% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $180.9 million in 2021, then surged by 68.1% to $304.0 million in 2022, then tumbled by 42.27% to $175.5 million in 2023, then increased by 19.89% to $210.4 million in 2024, then dropped by 23.77% to $160.4 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Total Current Liabilities are $160.4 million (Q4 2025), $161.8 million (Q3 2025), and $185.7 million (Q2 2025).